Prospective study on the efficacy and safety of rituximab therapy for nephropathy syndrome

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100045959

Enrollment

Unknown

Registered

2021-04-30

Start date

2021-05-01

Completion date

Unknown

Last updated

2021-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nephropathy syndrome

Interventions

rituximab HIGH dose group:rituximab 0.6g-1.1g

rituximab LOW dose group:rituximab 0.4g

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for nephrotic syndrome (24-hour urine protein quantification >= 3.5g/d, serum albumin = 3 months.

Exclusion criteria

Exclusion criteria: 1. Active infection or malignant tumor; 2. Existence of central nervous system diseases or symptoms; 3. Abnormal liver function: Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) exceeds the upper limit of normal 2 times; 4. Heart failure; 5. Participating in other research experiments and/or receiving or already receiving other immunosuppressive therapy (within 3 months); 6. Those with mental illness and poor compliance.

Design outcomes

Primary

Measure	Time frame
24 hours urine protein;serum creatinine;?????;B lymphocyte;	—

Countries

China

Contacts

Public ContactWei Xiansen

China-Japan Friendship Hospital

wxs3256@126.com+86 13810013426

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026